Form 8-K - Current report:
SEC Accession No. 0001493152-25-024618
Filing Date
2025-11-21
Accepted
2025-11-21 16:05:45
Documents
13
Period of Report
2025-11-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 45763
2 EX-10.1 ex10-1.htm EX-10.1 38456
  Complete submission text file 0001493152-25-024618.txt   258267

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE shph-20251120.xsd EX-101.SCH 3029
4 XBRL LABEL FILE shph-20251120_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE shph-20251120_pre.xml EX-101.PRE 22368
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3817
Mailing Address 401 PROFESSIONAL DRIVE SUITE 260 GAITHERSBURG MD 20879
Business Address 401 PROFESSIONAL DRIVE SUITE 260 GAITHERSBURG MD 20879 (240) 403-4212
Shuttle Pharmaceuticals Holdings, Inc. (Filer) CIK: 0001757499 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41488 | Film No.: 251507940
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)